Last updated: October 31, 2026
HEPLISAV-B has shifted Dynavax Technologies from a development-stage biotechnology company into a commercial vaccine business. The product’s two-dose schedule, differentiated CpG 1018 adjuvant, and strong adult immunogenicity support continued share gains against three-dose hepatitis B vaccines. Revenue growth has been driven by broader adult vaccination recommendations, increased pharmacy and employer adoption, and improved payer access. The principal commercial risks are concentration in one product, dependence on U.S. adult vaccination demand, competition from established hepatitis B vaccines, and the eventual loss of biologic reference-product exclusivity in November 2029.
What is HEPLISAV-B and how does it work?
HEPLISAV-B is a recombinant hepatitis B vaccine for adults age 18 years and older. Dynavax Technologies developed the vaccine using hepatitis B surface antigen combined with CpG 1018, a synthetic oligodeoxynucleotide adjuvant that activates Toll-like receptor 9 and enhances immune response.
The product is administered as two doses one month apart. Engerix-B and Recombivax HB generally require three doses over six months, although dosing schedules vary by product and patient population. The shorter HEPLISAV-B schedule reduces the number of patient visits and improves the probability that adults complete the series.
The FDA approved HEPLISAV-B on November 9, 2017, after earlier regulatory setbacks related to cardiovascular safety data and trial design. The approved indication covers prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. [1]
What is the FDA regulatory status of HEPLISAV-B?
HEPLISAV-B is an FDA-approved biologic licensed under Biologics License Application No. 125514. It is not an ordinary small-molecule product approved under an NDA.
The CDC’s adult hepatitis B vaccination policy expanded the addressable market in 2022. The Advisory Committee on Immunization Practices recommended routine hepatitis B vaccination for all adults ages 19 through 59 and for adults age 60 or older with risk factors or based on shared clinical decision-making. [2]
The policy change matters commercially because hepatitis B vaccination previously depended more heavily on identified risk factors. Universal adult recommendations increase demand from primary care, pharmacies, occupational health providers, prisons, substance-use treatment programs, and public-health departments.
How large is the HEPLISAV-B market?
The U.S. hepatitis B vaccine market is mature but underpenetrated among adults. Demand is supported by several factors:
- Universal adult vaccination recommendations for people ages 19 through 59.
- Low historical vaccination rates among adults.
- More frequent screening for hepatitis B and hepatitis C.
- Immigration and travel-related vaccination.
- Employer and health-care-worker vaccination.
- Higher demand from dialysis, correctional, behavioral-health, and substance-use-treatment settings.
- Operational value from a two-dose, one-month schedule.
HEPLISAV-B’s commercial opportunity is concentrated in adults rather than pediatric vaccination. Pediatric hepatitis B demand is largely supplied by combination vaccines and established childhood immunization programs.
How does HEPLISAV-B compare with Engerix-B and Recombivax HB?
| Attribute |
HEPLISAV-B |
Engerix-B |
Recombivax HB |
| Manufacturer |
Dynavax |
GSK |
Merck |
| Vaccine type |
Recombinant hepatitis B vaccine with CpG 1018 adjuvant |
Recombinant hepatitis B vaccine |
Recombinant hepatitis B vaccine |
| Adult primary schedule |
2 doses over 1 month |
Usually 3 doses over 6 months |
Usually 3 doses over 6 months |
| FDA adult indication |
Age 18 and older |
Broad age-based indications |
Broad age-based indications |
| Key commercial advantage |
Faster series completion and strong seroprotection |
Established distribution and formulary presence |
Established distribution and brand familiarity |
| Primary commercial weakness |
Single-product supplier and narrower historical market presence |
Longer dosing schedule |
Longer dosing schedule |
In the pivotal Phase 3 studies, HEPLISAV-B produced higher seroprotection rates than Engerix-B in adults, including older adults and patients with risk factors for weaker vaccine response. The shortened schedule also has practical value in settings where patients are difficult to retain for follow-up visits. [1]
HEPLISAV-B does not compete solely on clinical efficacy. The product competes on administration efficiency, series completion, inventory management, and the ability to vaccinate adults during a limited health-care encounter.
What has driven HEPLISAV-B revenue growth?
HEPLISAV-B revenue has followed an adoption curve typical of a differentiated vaccine launched into an established market. Early growth was limited by the 2017 launch timing, the COVID-19 pandemic, limited awareness, and the need to secure reimbursement and distribution access. Revenue accelerated as Dynavax expanded its commercial infrastructure and as adult vaccination policy broadened.
HEPLISAV-B financial trajectory
The following table summarizes Dynavax’s reported commercial progression. Figures are based on company annual reports and include reported product revenue where disclosed. [3]
| Fiscal year |
HEPLISAV-B commercial position |
Reported financial direction |
| 2017 |
FDA approval and initial launch |
No meaningful full-year commercial contribution |
| 2018 |
Early market introduction |
Limited launch revenue |
| 2019 |
Initial account and pharmacy expansion |
Revenue growth from a small base |
| 2020 |
COVID-19 disruption |
Slower adult vaccination activity |
| 2021 |
Recovery and broader account penetration |
Product revenue increased materially |
| 2022 |
Benefit from adult vaccination recommendations and channel expansion |
Strong year-over-year product growth |
| 2023 |
Continued commercial scaling |
HEPLISAV-B became Dynavax’s dominant revenue source |
Dynavax’s business model has become increasingly dependent on HEPLISAV-B product revenue. Collaboration and licensing income, including revenue tied to the CpG 1018 adjuvant platform, can create quarterly variability, but the recurring economic base is the hepatitis B vaccine.
The company has used a direct commercial organization and distributor relationships to target large physician practices, pharmacies, public-health departments, hospitals, dialysis providers, and institutional accounts. The product’s economic value is strongest where missed follow-up doses create a high risk of incomplete vaccination.
What is the revenue exposure to HEPLISAV-B?
HEPLISAV-B represents the central commercial asset in Dynavax’s portfolio. This creates operating leverage when vaccine demand rises, but it also creates concentration risk.
Key exposure points include:
- U.S. adult vaccination volume.
- Reimbursement and payer coverage.
- Government and institutional purchasing.
- Manufacturing continuity.
- Competitive pricing.
- Execution by a single-product commercial organization.
- The timing of additional international approvals.
A decline in adult vaccination rates, loss of a major account, or manufacturing disruption would affect Dynavax more directly than it would a diversified vaccine company such as GSK or Merck.
When does HEPLISAV-B lose biologic exclusivity?
HEPLISAV-B received the FDA’s 12-year reference-product exclusivity applicable to licensed biologics. Based on the November 9, 2017 approval date, the statutory exclusivity period runs to November 9, 2029, subject to the operation of the Biologics Price Competition and Innovation Act and any applicable pediatric exclusivity or regulatory adjustments. [4]
The 12-year period prevents FDA approval of a biosimilar referencing HEPLISAV-B during the statutory exclusivity period. It does not eliminate separate patent rights, nor does it automatically prevent another manufacturer from pursuing an independent BLA or a different vaccine development pathway.
Is there an Orange Book listing for HEPLISAV-B?
HEPLISAV-B is a biologic licensed under a BLA rather than a conventional drug approved under an NDA. The Orange Book is principally associated with approved drug products and patent certifications under the Hatch-Waxman framework. Biologic reference products are generally evaluated through the Purple Book and the BPCIA framework rather than through the standard Orange Book listing process. [5]
As a result, conventional Orange Book patent-certification analysis, including a typical Paragraph IV challenge, is not the primary pathway for HEPLISAV-B.
Are there Paragraph IV challenges or biosimilar risks for HEPLISAV-B?
No material public Paragraph IV litigation is associated with HEPLISAV-B because the product is not primarily regulated through the NDA-Hatch-Waxman pathway.
The more relevant post-2029 risk is a competing biologic or vaccine product. A biosimilar applicant would need to establish biosimilarity to the reference product under the BPCIA. For a vaccine containing a proprietary adjuvant system, manufacturing comparability and analytical characterization may be more complex than for a conventional recombinant protein product.
There was no FDA-approved biosimilar to HEPLISAV-B as of the latest publicly reported period covered by Dynavax’s 2023 annual report. [3]
What is the patent strength of the HEPLISAV-B estate?
HEPLISAV-B protection has several layers:
- The BLA’s 12-year regulatory exclusivity.
- Patents covering CpG 1018 and related immunostimulatory oligonucleotide technology.
- Patents covering vaccine compositions and adjuvant-antigen combinations.
- Manufacturing and formulation know-how.
- Clinical and regulatory data that create time and cost barriers for competitors.
The commercial value of the patent estate is more difficult to assess than the regulatory exclusivity because patent scope, terminal disclaimers, maintenance status, prosecution history, and claim validity must be evaluated patent by patent. The strongest practical barrier may be the combination of regulatory exclusivity, manufacturing know-how, clinical data, and channel relationships rather than any single patent.
What formulations and manufacturing processes are protected?
The commercial formulation combines hepatitis B surface antigen with CpG 1018. Protection may extend across the adjuvant composition, antigen-adjuvant ratio, dosing regimen, immune response, and manufacturing process, depending on the specific issued claims.
Manufacturing barriers include:
- Consistent production of recombinant hepatitis B surface antigen.
- Control of CpG 1018 purity and structure.
- Adjuvant-antigen formulation stability.
- Sterile fill-finish capacity.
- Release testing and lot consistency.
- Validation of the two-dose clinical regimen.
A competing manufacturer could potentially develop a different adjuvant or an alternative hepatitis B vaccine without copying the HEPLISAV-B formulation. That route would require new clinical evidence and regulatory review, increasing development cost and launch time.
Which companies compete with HEPLISAV-B?
GSK
GSK’s Engerix-B is the most established direct adult competitor. GSK has broad vaccine distribution, longstanding provider relationships, and a large institutional sales network. Its key disadvantage relative to HEPLISAV-B is the longer conventional dosing schedule.
Merck
Merck’s Recombivax HB competes through brand recognition, established procurement channels, and integration with Merck’s broader vaccine portfolio. It also faces the operational disadvantage of a longer adult vaccination schedule.
Pfizer and combination-vaccine suppliers
Combination vaccines and pediatric hepatitis B products compete for institutional purchasing and vaccination budgets, although they are less direct substitutes for adult HEPLISAV-B use.
VBI Vaccines and PreHevbrio
PreHevbrio received FDA approval for adults in 2021 but VBI Vaccines later discontinued commercial operations in the United States and withdrew the product from the U.S. market. That reduced near-term branded competition for HEPLISAV-B. [6]
What patent litigation and settlement risks affect HEPLISAV-B?
The principal legal risk is not an established Paragraph IV dispute. It is the possibility of future patent challenges, independent vaccine development, or biosimilar competition as the 2029 exclusivity date approaches.
Potential legal scenarios include:
| Scenario |
Commercial effect |
| No credible follow-on entrant before 2029 |
Dynavax retains broad pricing and market-access control |
| Patent challenge without immediate launch |
Litigation expense and contracting uncertainty |
| Independent competing BLA |
Longer development timeline but potentially meaningful post-2029 competition |
| Biosimilar application |
Price pressure and payer substitution risk |
| Competing adjuvanted hepatitis B vaccine |
Direct clinical and formulary challenge |
| Settlement before launch |
Potential delayed entry with agreed commercialization terms |
No major public settlement governing generic or biosimilar entry for HEPLISAV-B had been disclosed in the latest cited company filings.
What is the international market opportunity?
Dynavax has pursued international expansion through regulatory filings, commercial partnerships, and licensing arrangements. International opportunity is constrained by country-specific reimbursement, vaccination policies, local manufacturing requirements, and established procurement contracts.
The largest near-term economic opportunity remains the United States because:
- The FDA label covers a broad adult population.
- ACIP recommendations support routine adult vaccination.
- The U.S. pharmacy channel can administer adult vaccines at scale.
- Dynavax has built U.S. commercial infrastructure.
- Hepatitis B vaccination remains underpenetrated among adults.
International sales can diversify geographic exposure, but they are unlikely to displace the U.S. market as the core revenue driver in the near term.
How does HEPLISAV-B compare with competing vaccine franchises?
HEPLISAV-B has a more concentrated but potentially more efficient commercial profile than hepatitis B products sold by diversified vaccine companies.
| Factor |
Dynavax and HEPLISAV-B |
GSK and Engerix-B |
Merck and Recombivax HB |
| Portfolio breadth |
Narrow |
Broad vaccine portfolio |
Broad pharmaceutical and vaccine portfolio |
| Adult hepatitis B differentiation |
Two-dose schedule and CpG 1018 |
Established product and distribution |
Established product and distribution |
| Revenue concentration |
High |
Low |
Low |
| Commercial resilience |
Dependent on one primary product |
Supported by multiple vaccines |
Supported by multiple businesses |
| Upside driver |
Adult market conversion |
Portfolio cross-selling |
Institutional and brand reach |
| Main risk |
Product concentration and post-2029 entry |
Longer schedule |
Longer schedule |
What generic launch scenarios exist for HEPLISAV-B?
A conventional generic launch is unlikely to be the primary post-exclusivity scenario because HEPLISAV-B is a biologic vaccine. The more relevant possibilities are:
- A biosimilar or interchangeable biologic, if the product and evidence package meet FDA requirements.
- An independently developed hepatitis B vaccine with a different adjuvant.
- A rival two-dose vaccine using another immunostimulatory technology.
- Price competition from existing three-dose vaccines.
- Expanded use of combination vaccines in adult populations.
The first meaningful competitive pressure could appear through contracting rather than automatic pharmacy substitution. Vaccine purchasing decisions often depend on public-health contracts, account-level formularies, administration costs, and supply reliability.
Key Takeaways
- HEPLISAV-B is Dynavax’s primary commercial asset and the company’s main source of recurring product revenue.
- Its two-dose, one-month schedule differentiates it from Engerix-B and Recombivax HB.
- The 2022 ACIP recommendation for routine adult hepatitis B vaccination materially expanded the addressable market.
- FDA reference-product exclusivity is expected to run through November 9, 2029, based on the November 9, 2017 approval date.
- HEPLISAV-B is regulated as a biologic, so biosimilar and BPCIA analysis is more relevant than a conventional Paragraph IV framework.
- The commercial patent position includes CpG 1018 technology, vaccine composition, formulation, and manufacturing know-how.
- Dynavax has high product concentration risk because HEPLISAV-B supplies the core commercial base.
- The principal growth opportunity is conversion of under-vaccinated U.S. adults through pharmacies, primary care, public-health programs, and institutional accounts.
- The principal long-term risk is post-2029 competition from a biosimilar, an independently developed adjuvanted vaccine, or lower-priced established products.
FAQs About HEPLISAV-B Market and Exclusivity
Is HEPLISAV-B more effective than Engerix-B?
Clinical trials showed higher seroprotection rates for HEPLISAV-B than Engerix-B in several adult populations. Its two-dose schedule also improves convenience and may increase series completion.
Can HEPLISAV-B be substituted automatically at the pharmacy?
Automatic substitution depends on state law, payer policy, product classification, and whether a follow-on product receives an interchangeable designation. The two-dose schedule does not by itself create automatic substitution rights.
Does HEPLISAV-B have orphan-drug exclusivity?
No. HEPLISAV-B is an adult hepatitis B vaccine with broad population coverage, not an orphan product.
What is the main manufacturing risk for HEPLISAV-B?
The main risks are supply continuity, quality control for CpG 1018 and the recombinant antigen, sterile fill-finish capacity, and the ability to scale production without lot-release delays.
Can Dynavax license CpG 1018 without licensing HEPLISAV-B?
Yes. CpG 1018 is a platform technology that can be licensed separately for other vaccines. Such licensing can generate collaboration or supply revenue, but it does not eliminate Dynavax’s financial dependence on HEPLISAV-B.
References
- U.S. Food and Drug Administration. (2017). HEPLISAV-B prescribing information. https://www.fda.gov
- Centers for Disease Control and Prevention. (2022). Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and Mortality Weekly Report, 71(13), 477-483. https://www.cdc.gov/mmwr
- Dynavax Technologies Corporation. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
- Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- VBI Vaccines Inc. (2023). Corporate updates and PreHevbrio U.S. commercial discontinuation disclosures. https://www.sec.gov
